BioLineRx (BLRX) Tops Q1 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to BioLineRx (BLRX) Tops Q1 EPS by 13c

BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 11, 2022 7:00 AM EDT

- On track to submit New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation in mid-2022, consistent with prior guidance -

- Progressing critical Motixafortide pre-launch activities while maintaining full optionality on commercialization strategies -

- Cash and cash equivalents at March 31, 2022 of $50.6 million, sufficient to fund operations, as currently planned, into first half of 2024 -

- Management to hold conference call today, May 11, at 10:00 am EDT -

TEL AVIV,... More